Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision

Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…

AI Summary: GSK has licensed its investigational drug linerixibat to Alfasigma for $300 million upfront, transferring global rights as the therapy nears regulatory decisions for cholestatic liver itch. The deal accelerates Alfasigma’s rare-disease ambitions while allowing GSK to reposition its pipeline — a tidy corporate shuffle with real implications for patients with debilitating pruritus.

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #healthcarefinance

What to know about fatty liver disease and why it's so common

2 months / medicalxpress

GSK liver drug wins FDA approval

2 months / endpoints / Nicole DeFeudis

Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision

2 months / medcitynews / Frank Vinluan

GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfront

2 months / endpoints / Reynald Castaneda

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision

Related Stories